Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1978 Jul;54(633):477–484. doi: 10.1136/pgmj.54.633.477

Treatment of congestive cardiomyopathy.

W H Abelmann
PMCID: PMC2425121  PMID: 360197

Abstract

Although the majority of patients with cardiomyopathy are in the category of primary or idiopathic cardiomyopathy, for which therapy is symptomatic and non-specific, there are a number of secondary forms of cardiomyopathy for which specific therapy is available, thus giving impetus to prompt and accurate diagnosis. Among inflammatory lesions, brucellosis, psittacosis and toxoplasmosis are examples. Treatable metabolic causes include thyrotoxicosis and thiamine deficiency, the latter as well as calorie-protein malnutrition are also preventable. There is presumptive evidence that the cardiomyopathy of haemochromatosis is benefited by repeated phlebotomies. Symptomatic relief of obstructive cardiomyopathy is achieved by beta-adrenergic blockade, although resection of obstructing myocardium still has a place. The therapeutic approach to the vast majority of cases of congestive cardiomyopathy is non-specific, comprising controlled activity, sodium restriction, digitalis and diuretics. Vasodilators and, occasionally, beta-adrenergic blockade may be beneficial. Pacemakers may be life-saving, whereas the place of anti-arrhythmics remains uncertain. Transplantation warrants further application. Valve replacement has little to offer. Primary prevention, comprising balanced nutrition, vaccines and genetic counselling, merits wider application. In individuals at risk or already afflicted, programmes of secondary prevention should include good nutrition, abstinence from alcohol and protection from drugs and toxins.

Full text

PDF
477

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akbarian M., Yankopoulos N. A., Abelmann W. H. Hemodynamic studies in beriberi heart disease. Am J Med. 1966 Aug;41(2):197–212. doi: 10.1016/0002-9343(66)90016-7. [DOI] [PubMed] [Google Scholar]
  2. Akhtar N., Mikulic E., Cohn J. N., Chaudhry M. H. Hemodynamic effect of dobutamine in patients with severe heart failure. Am J Cardiol. 1975 Aug;36(2):202–205. doi: 10.1016/0002-9149(75)90526-3. [DOI] [PubMed] [Google Scholar]
  3. Aronow W. S., Greenfield R. S., Alimadadian H., Danahy D. T. Effect of the vasodilator trimazosin versus placebo on exercise performance in chronic left ventricular failure. Am J Cardiol. 1977 Nov;40(5):789–793. doi: 10.1016/0002-9149(77)90198-9. [DOI] [PubMed] [Google Scholar]
  4. Burch G. E., Giles T. D. Prolonged bed rest in the management of patients with cardiomyopathy. Cardiovasc Clin. 1972;4(1):375–387. [PubMed] [Google Scholar]
  5. Duhme D. W., Greenblatt D. J., Koch-Weser J. Reduction of digoxin toxicity associated with measurement of serum levels. A report from the Boston Collaborative Drug Surveillance Program. Ann Intern Med. 1974 Apr;80(4):516–519. doi: 10.7326/0003-4819-80-4-516. [DOI] [PubMed] [Google Scholar]
  6. ELSON S. H., ABELMANN W. H. EFFECTS OF MUSCULAR ACTIVITY UPON THE ACUTE MYOCARDITIS OF C3H MICE INFECTED WITH TRYPANOSOMA CRUZI. Am Heart J. 1965 May;69:629–636. doi: 10.1016/0002-8703(65)90245-0. [DOI] [PubMed] [Google Scholar]
  7. Easley R. M., Jr, Schreiner B. F., Jr, Yu P. N. Reversible cardiomyopathy associated with hemochromatosis. N Engl J Med. 1972 Oct 26;287(17):866–867. doi: 10.1056/NEJM197210262871708. [DOI] [PubMed] [Google Scholar]
  8. Franciosa J. A., Limas C. J., Guiha N. H., Rodriguera E., Cohn J. N. Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet. 1972 Mar 25;1(7752):650–654. doi: 10.1016/s0140-6736(72)90460-6. [DOI] [PubMed] [Google Scholar]
  9. Franciosa J. A., Pierpont G., Cohn J. N. Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients. Ann Intern Med. 1977 Apr;86(4):388–393. doi: 10.7326/0003-4819-86-4-388. [DOI] [PubMed] [Google Scholar]
  10. Gatmaitan B. G., Chason J. L., Lerner A. M. Augmentation of the virulence of murine coxsackie-virus B-3 myocardiopathy by exercise. J Exp Med. 1970 Jun 1;131(6):1121–1136. doi: 10.1084/jem.131.6.1121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Goodwin J. F. Treatment of the cardiomyopathies. Am J Cardiol. 1973 Sep 7;32(3):341–351. doi: 10.1016/s0002-9149(73)80144-4. [DOI] [PubMed] [Google Scholar]
  12. Gould L., Zahir M., DeMartino A., Gomprecht R. F. Cardiac effects of a cocktail. JAMA. 1971 Dec 20;218(12):1799–1802. [PubMed] [Google Scholar]
  13. KILBOURNE E. D., WILSON C. B., PERRIER D. The induction of gross myocardial lesions by a Coxsackie (pleurodynia) virus and cortisone. J Clin Invest. 1956 Apr;35(4):362–370. doi: 10.1172/JCI103286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Loeb H. S., Bredakis J., Gunner R. M. Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure. Circulation. 1977 Feb;55(2):375–378. doi: 10.1161/01.cir.55.2.375. [DOI] [PubMed] [Google Scholar]
  15. Mahoney M. J., Haseltine F. P., Hobbins J. C., Banker B. Q., Caskey C. T., Golbus M. S. Prenatal diagnosis of Duchenne's muscular dystrophy. N Engl J Med. 1977 Nov 3;297(18):968–973. doi: 10.1056/NEJM197711032971803. [DOI] [PubMed] [Google Scholar]
  16. Massie B., Chatterjee K., Werner J., Greenberg B., Hart R., Parmley W. W. Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure. Am J Cardiol. 1977 Nov;40(5):794–801. doi: 10.1016/0002-9149(77)90199-0. [DOI] [PubMed] [Google Scholar]
  17. Mikulic E., Cohn J. N., Franciosa J. A. Comparative hemodynamic effects of inotropic and vasodilator drugs in severe heart failure. Circulation. 1977 Oct;56(4 Pt 1):528–533. doi: 10.1161/01.cir.56.4.528. [DOI] [PubMed] [Google Scholar]
  18. PEARCE J. M. Heart disease and filtrable viruses. Circulation. 1960 Mar;21:448–455. doi: 10.1161/01.cir.21.3.448. [DOI] [PubMed] [Google Scholar]
  19. Rider A. K., Copeland J. G., Hunt S. A., Mason J., Specter M. J., Winkle R. A., Bieber C. P., Billingham M. E., Dong E., Jr, Griepp R. B. The status of cardiac transplantation, 1975. Circulation. 1975 Oct;52(4):531–539. doi: 10.1161/01.cir.52.4.531. [DOI] [PubMed] [Google Scholar]
  20. Rossen R. M., Alderman E. L., Harrison D. C. Circulatory response to vasodilator therapy in congestive cardiomyopathy. Br Heart J. 1976 Jul;38(7):695–700. doi: 10.1136/hrt.38.7.695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Skinner C., Kenmure A. C. Haemochromatosis presenting as congestive cardiomyopathy and responding to venesection. Br Heart J. 1973 Apr;35(4):466–468. doi: 10.1136/hrt.35.4.466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Soroff H. S., Ruiz U., Birtwell W. C., Many M., Giron F., Deterling R. A., Jr Assisted circulation by external pressure variation. Isr J Med Sci. 1969 Jul-Aug;5(4):506–514. [PubMed] [Google Scholar]
  23. Waagstein F., Hjalmarson A., Varnauskas E., Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975 Oct;37(10):1022–1036. doi: 10.1136/hrt.37.10.1022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wilhelmsen L., Sanne H., Elmfeldt D., Grimby G., Tibblin G., Wedel H. A controlled trial of physical training after myocardial infarction. Effects on risk factors, nonfatal reinfarction, and death. Prev Med. 1975 Dec;4(4):491–508. doi: 10.1016/0091-7435(75)90035-3. [DOI] [PubMed] [Google Scholar]
  25. Yankopoulos N. A., Kawai C., Federici E. E., Adler L. N., Abelmann W. H. The hemodynamic effects of ouabain upon the diseased left ventricle. Am Heart J. 1968 Oct;76(4):466–480. doi: 10.1016/0002-8703(68)90133-6. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES